Application of androgen receptor inhibitor and cytokine in preparation of T cell with lasting killing capability
By targeting the inhibition of androgen receptors and binding to IL-15 and IL-7, T cells were incubated, and the problem of limited effects of T cells in solid tumors was solved, which significantly improved the anti-tumor properties and durability of T cells, achieving Improved lasting killing ability.
Patent Information
- Application Number
- CN202411003585.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-12
AI Technical Summary
Existing T cells have limited effect in solid tumors, mainly due to the depletion evolution of therapeutic T cells that limits the durability of antitumor responses, and the androgen receptor signaling pathway leads to gender bias and immune checkpoint inhibition of antitumor immune responses The therapeutic effect of the agent is limited.
T cells with persistent killing ability are prepared by targeting inhibitory androgen receptors, combining cytokines IL-15 and IL-7, using small-molecule compounds or inhibitory polynucleotides such as shRNA or siRNA, as well as small molecules Compounds such as ARV-110 and other androgen receptor inhibitors, combined with the concentration of IL-15 and IL-7 is within the range of 1 to 50 ng/mL and 0.1 to 10 nM, and incubated for 24 hours to 20 days to improve the dry maintenance of T cells. Ability and anti-tumor properties.
It significantly improves the stem-maintenance and anti-tumor effects of T cells, ensures killing effect over a long period of time, enhances the anti-tumor properties and durability of T cells, and improves the tumor treatment effect.
Smart Images

Figure BDA0004962439560000141 
Figure BDA0004962439560000151 
Figure BDA0004962439560000152
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and more specifically, the present invention relates to the application of androgen receptor inhibitors and cytokines in preparing T cells with persistent killing ability. Background Art
[0002] T cells are key cells in exerting anti-tumor immune responses and determine the success or failure of tumor immunotherapy. T cell therapy is a new type of "living" drug developed based on the anti-tumor properties of T cells. It is amplified in vitro or engineered and then adoptively infused into tumor patients to exert tumor-killing function. Although T cell therapy has revolutionized the existing tumor treatment landscape, it has limited effects in solid tumors. The reason is that the exhaustive evolution of therapeutic T cells in the tumor limits the durability of the anti-tumor response. Therefore, it is urgent to develop methods and strategies to optimize the anti-tumor function and durability of therapeutic T cells.
[0003] Androgen receptor is a hormone-dependent transcription factor that senses androgen levels in the cell environment and then enters the nucleus to participate in the regulation of gene expression patterns. It is widely involved in the functional regulation of various immune cells. The androgen receptor signaling pathway has been found to drive male T cell exhaustion and impaired function, leading to gender bias in anti-tumor immune responses. In addition, androgen receptor activity also limits the therapeutic effect of immune checkpoint inhibitors. Therefore, androgen receptor is a potential target for enhancing the anti-tumor properties of therapeutic T cells. Summary of the invention
[0004] The object of the present invention is to provide the use of androgen receptor inhibitors and cytokines in preparing T cells.
[0005] In the first aspect of the present invention, there is provided the use of an androgen receptor inhibitor and a cytokine in preparing T cells with persistent killing ability, wherein the cytokines are IL-15 and IL-7; and the androgen receptor inhibitor is a small molecule compound, an inhibitory polynucleotide, or a combination thereof.
[0006] In one or more embodiments, the androgen receptor inhibitor is a shRNA or siRNA targeting an androgen receptor coding sequence; preferably, the shRNA has a sequence as shown in SEQ ID NO: 3 or SEQ ID NO: 4, or a sequence having at least 90% sequence identity with the sequence shown in SEQ ID NO: 3 or SEQ ID NO: 4.
[0007] In one or more embodiments, the androgen receptor inhibitor is a small molecule compound that has the function of degrading androgen receptor protein; preferably ARV-110, ARD-61 or UT-34.
[0008] In one or more embodiments, the concentrations of IL-15 and IL-7 are 1 to 50 ng / mL, preferably 10 to 20 ng / mL, respectively.
[0009] In one or more embodiments, the concentration of the androgen receptor inhibitor is 0.1 to 10 nM, preferably 1 to 5 nM.
[0010] In one or more embodiments, the T cells include: CD8 + T cells, CD4 + T cells, CD44 + T cells, CD62L + T cells, TCF1 + T cells, TCF1 + TIM3 - T cells, SLAMF6 + TIM3 - T cells, CD44 + CD62L + T cells, IFNγ + TNFα + T cells, Thy1.1 + T cells, Ki67 + T cells, CD107a + Granzyme B + T cells, TCR-T cells and CAR-T cells.
[0011] In the second aspect of the present invention, a method for preparing T cells with persistent killing ability is provided, the method comprising: incubating T cells with an androgen receptor inhibitor, cytokines IL-15 and IL-7 to obtain T cells with persistent killing ability; wherein the androgen receptor inhibitor is a small molecule compound, an inhibitory polynucleotide, or a combination thereof.
[0012] In one or more embodiments, the androgen receptor inhibitor is as defined in any of the embodiments of the invention.
[0013] In one or more embodiments, the concentrations of the androgen receptor inhibitor, cytokines IL-15 and IL-7 are as defined in any embodiment of the invention.
[0014] In one or more embodiments, the T cells having persistent killing ability are as defined in any embodiment of the present invention.
[0015] In one or more embodiments, the incubation time is 24 hours to 20 days, more preferably 5-10 days; and / or, preferably, the density of T cells during incubation is 1×10 6 / mL~2×106 / mL.
[0016] In a third aspect of the present invention, a T cell with persistent killing ability is provided, wherein the T cell is prepared by the method described in any embodiment of the present invention.
[0017] In a fourth aspect of the present invention, a composition is provided, comprising an androgen receptor inhibitor, cytokines IL-15 and IL-7, wherein the androgen receptor inhibitor is a small molecule compound, an inhibitory polynucleotide, or a combination thereof.
[0018] In one or more embodiments, the androgen receptor inhibitor is as defined in any of the embodiments of the invention.
[0019] In one or more embodiments, the concentrations of the androgen receptor inhibitor, cytokines IL-15 and IL-7 are as defined in any embodiment of the invention.
[0020] In one or more embodiments, the composition further comprises T cells with persistent killing ability as described in any embodiment of the present invention.
[0021] In the fifth aspect of the present invention, a pharmaceutical composition is provided, which includes an androgen receptor inhibitor, cytokines IL-15 and IL-7, and a pharmaceutically acceptable carrier; wherein the androgen receptor inhibitor is a small molecule compound, an inhibitory polynucleotide, or a combination thereof.
[0022] In one or more embodiments, the androgen receptor inhibitor is as defined in any of the embodiments of the invention.
[0023] In one or more embodiments, the concentrations of the androgen receptor inhibitor, cytokines IL-15 and IL-7 are as defined in any embodiment of the invention.
[0024] In one or more embodiments, the pharmaceutical composition further comprises T cells with persistent killing ability as described in any embodiment of the present invention.
[0025] In a sixth aspect of the present invention, a kit or a medicine box is provided, which comprises an androgen receptor inhibitor, cytokines IL-15 and IL-7, wherein the androgen receptor inhibitor is a small molecule compound, an inhibitory polynucleotide, or a combination thereof.
[0026] In one or more embodiments, the kit or medicine box further contains the T cells with persistent killing ability described in any embodiment of the present invention, or the composition described in any embodiment of the present invention, or the pharmaceutical composition described in any embodiment of the present invention.
[0027] In one or more embodiments, the androgen receptor inhibitor is as defined in any of the embodiments of the invention.
[0028] In one or more embodiments, the concentrations of the androgen receptor inhibitor, cytokines IL-15 and IL-7 are as defined in any embodiment of the invention.
[0029] In the seventh aspect of the present invention, there is provided the use of the T cells with persistent killing ability described in any embodiment of the present invention, or the composition described in any embodiment of the present invention, or the pharmaceutical composition described in any embodiment of the present invention in the preparation of a drug for treating tumors.
[0030] In one or more embodiments, the tumor is a primary or metastatic tumor.
[0031] In one or more embodiments, the tumor is selected from one or more of the following: colon cancer, liver cancer, small cell lung cancer, non-small cell lung cancer, melanoma, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, gastric cancer, Kaposi's sarcoma, and squamous cell carcinoma.
[0032] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 , The results of knocking down the androgen receptor (AR) in T cells using shRNA, and detecting the AR gene transcription level and protein expression level. Figure 1 The left is the result of real-time fluorescence quantitative PCR. Figure 1 The right side shows the results of Western Blotting.
[0034] Figure 2 , knocked down the AR gene expression of T cells, and analyzed the T cell effector cytokine secretion ability, memory-like subset formation, and stemness maintenance ability in vitro; AR knocked down T cells were therapeutically adoptively transferred into tumor-bearing mice, and the tumor volume detection results of mice were shown in Figure 3.
[0035] (A) AR knockdown T cells were incubated with PMA / ionomycin (containing protein transport inhibitor) for 5 h, and IFN-γ and TNF-α double positive (IFN-γ + TNF-α + )CD8 + Analysis of T cell subset proportions.
[0036] (B) AR knockdown T cells were reactivated with mouse anti-CD3 and anti-CD28 antibodies and were CD44 and CD62L double positive (CD44 + CD62L+ )Memory-like CD8 + Analysis of T cell subset proportions.
[0037] (C) Analysis of the expression levels of stemness-related molecular markers (SLAMF6) and transcription factors (TCF1). After AR knockdown T cells were reactivated using mouse anti-CD3 and CD28 antibodies, PD1 + CD44 + CD8 + SLAMF6 in T cells + TIM3 - T cell stem-like cell subsets (left), and PD1 + CD44 + CD8 + TCF1 in T cells + Proportional analysis of TIM3-T stem-like cell subsets (right).
[0038] (D) Analysis of AR knockdown in 2C-TCR CD8 + T cell therapy effect. AR knockdown T cells were adoptively infused into B16-EGFR-SIY tumor-bearing mice via tail vein (2×10 6 The tumor curve was drawn.
[0039] Figure 3 , degrade T cell androgen receptor protein, and analyze the in vitro degradation efficiency of androgen receptor protein, the formation of T cell memory-like subpopulations, and the test results of T cell stemness maintenance ability.
[0040] (A) The structural formula of AR degrader ARV-110 (top) and Western Blotting results of AR protein degradation (bottom), with DMSO treatment as the control and Actin as the internal reference.
[0041] (B) Activated CD8 + After T cells were treated with DMSO and ARV-110, CD44 and CD62L double positive (CD44 + CD62L + )Memory-like CD8 + Analysis of T cell subset induction ratio.
[0042] (C) Fluorescence quantitative PCR detected the relative expression of stemness transcription factors Tcf7 (left) and Klf2 (right) in T cells.
[0043] Figure 4 , using ARV-110 to degrade 2C-TCR CD8 +After the AR protein of T cells was expressed, it was adoptively transferred into B16-EGFR-SIY tumor-bearing mice for therapeutic purposes, and the tumor growth curve was recorded and plotted, with DMSO treatment as the control.
[0044] Figure 5 , AR protein degradation 2C-TCR CD8 + T cells were therapeutically adopted and infused into tumor-bearing mice. Ten days later, the infiltration and proliferation of therapeutic T cells in the mice, as well as the cytokine secretion capacity were analyzed.
[0045] (A) AR-degraded 2C-TCR CD8 + T cell infiltration in the tumor (Thy1.1 is a protein tag for adoptively transferred therapeutic T cells).
[0046] (B) Detection of therapeutic 2C-TCR CD8 in tumors + Ki67 positive T cells (Ki67 + ) T cell subset ratio, analysis of AR-degraded 2C-TCR CD8 + Proliferation of T cells in tumors.
[0047] (C) Detection of therapeutic 2C-TCR CD8 in tumors + The effector cytokine secretion and cytotoxic activity of T cells, including IFN-γ and TNF-α double positive (IFN-γ + TNF-α + )CD8 + T cell subset ratios, and CD107a and Granzyme B double positive (CD107a + Granzyme B + )CD8 + T cell subset ratio.
[0048] (D) Detection of IFN-γ and TNF-α double positive in tumor draining lymph nodes (IFN-γ + TNF-α + ) Therapeutic 2C-TCRCD8 + T cell subset ratio.
[0049] Figure 6 , AR gene knockdown 2C-TCR CD8 + T cells were cultured with or without the combination of IL-7 and IL-15 cytokines, and the proportion of memory-like subset formation, proliferation ability, and stemness maintenance ability were analyzed.
[0050] (A) IL-7 and IL-15 cytokine combination incubation combined with AR gene knockdown in T cells had an effect on memory-like 2C-TCRCD8 + T cell subsets (CD44 + CD62L + The left picture is a representative flow chart, and the right picture is a statistical chart.
[0051] (B) IL-7 and IL-15 cytokine combination incubation combined with AR gene knockdown in T cells had an effect on 2C-TCR CD8 + Effects of T cell proliferation and stemness (mediated by TCF1 + Ki67 + The left picture is a representative flow cytometry picture, and the right picture is a statistical picture. DETAILED DESCRIPTION
[0052] One of the reasons why existing T cells have limited effects in solid tumors is that the exhaustion of T cells in the tumor limits the durability of anti-tumor responses. Therefore, it is urgent to develop methods and strategies to optimize the anti-tumor function and persistence of T cells.
[0053] After in-depth research, the inventors found that by targeting androgen receptor protein inhibition in T cells and combining cytokines IL-15 and IL-7, T cells with persistent killing ability can be prepared. The T cells showed an improvement in the ability to maintain stemness and were able to maintain a high level of killing effect for a long time after tumor inoculation, thus improving the anti-tumor effect and persistence of T cells.
[0054] Therefore, the present invention provides the use of androgen receptor inhibitors and cytokines in preparing T cells with persistent killing ability, wherein the cytokines are IL-15 and IL-7; the androgen receptor inhibitor is a small molecule compound, an inhibitory polynucleotide, or a combination thereof.
[0055] Androgen receptor inhibitors
[0056] In this article, the term "androgen receptor", abbreviated as AR, also known as NR3C4, HUMARA, AMAX1, DHTR or AIS, is a transcription factor transcribed from the X-chromosome gene. Like other steroid receptors, the androgen receptor has three key domains, including the DNA binding domain (DBD), the N-terminal transactivation domain (NTD) and the C-terminal ligand binding domain (LBD). The activation of the androgen receptor molecule undergoes multiple steps, including dissociation from the partner protein, post-translational modification of the protein, binding to the ligand and dimerization. The activated androgen receptor complex translocates to the cell nucleus, binds to the auxiliary activator protein to form a co-activator transcription factor, and then enters the open chromatin region of the target gene to regulate gene expression. Androgen receptors are widely distributed in various cells, including thymic stromal cells and immune cells, and participate in physiological and pathological processes.
[0057] The term "androgen receptor protein" refers to a protein of SEQ ID NO: 1 (human AR protein sequence, 920aa) or SEQ ID NO: 2 (mouse AR protein sequence, 899aa) sequence having androgen receptor protein activity. The androgen receptor coding sequence is a nucleic acid sequence (DNA or RNA) encoding an androgen receptor protein. The term also includes variant forms of SEQ ID NO: 1 or SEQ ID NO: 2 sequences having the same function as the androgen receptor protein. These variant forms include (but are not limited to): deletion, insertion and / or substitution of several / one or more (usually 1-50, preferably 1-30, more preferably 1-20, most preferably 1-10, and more preferably 1-8, 1-5) amino acids, and addition or deletion of one or several (usually within 20, preferably within 10, and more preferably within 5) amino acids at the C-terminus and / or N-terminus. For example, in the art, when amino acids with similar or similar properties are substituted, the function of the protein is usually not changed. For another example, adding or deleting one or more amino acids at the C-terminus and / or N-terminus usually does not change the function of the protein.
[0058] Herein, the "androgen receptor inhibitor" can achieve the inhibition by targeted inhibition of the expression or activity of androgen receptor. Agents that target the inhibition of the expression or activity of androgen receptor protein include inhibitory molecules that interfere with the transcription and / or expression of protein encoding genes or downregulate protein activity, and the inhibitory molecules use proteins or their encoding genes or transcripts as inhibition targets.
[0059] In one or more embodiments, the inhibitory molecule is selected from the group consisting of a small molecule compound, an inhibitory polynucleotide, or a combination thereof.
[0060] In an exemplary embodiment, the agent for targeted inhibition of the expression or activity of the androgen receptor is an inhibitory polynucleotide with the transcript of the protein-coding gene as the inhibition target, such as but not limited to: siRNA, shRNA. The inhibitory polynucleotide can reduce the expression or activity of the androgen receptor by more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90% or more. The "reduction" includes "reduction", "inhibition" or "weakening". The reduction is usually relative to the control, and the control can be, for example, a control group into which scrambleRNA is transferred. Exemplarily, the inhibitory polynucleotide is shRNA, which has a sequence as shown in SEQ ID NO:3 or SEQ ID NO:4, or a sequence having at least 90% (e.g., at least 91%, 92%, 93%, 95%, 97%, 98%, 99% or more) sequence identity with the sequence shown in SEQ ID NO:3 or SEQ ID NO:4.
[0061] In an exemplary embodiment, the reagent for targeting and inhibiting the expression or activity of androgen receptor is a small molecule compound. The small molecule compound can be a small molecule compound that competitively binds to androgen receptor with androgen, such as but not limited to: Enzalutamide, Bicalutamide, Apalutamide, Flutamide, Galeterone. The small molecule compound can also be a small molecule compound with the function of degrading androgen receptor protein, including intracellular ubiquitin-proteasome targeting chimeras (Proteolysis-Targetingchimeras, PROTAC), lysosome targeting chimeras (Lysosome-Targeting chimeras, LYTAC), autophagy targeting chimeras (Autophagy-Targeting chimeras, AUTOTA), autophagy tethering compounds (Autophagy-Tethering compounds, ATTEC), and protein degradation technology that directly recruits 26S proteasomes, such as chemical degradation inducers (CIDEs) or ADRM1-mediated ubiquitin-independent degradation products (UIDs). Preferably, the small molecule compound is a drug that utilizes the ubiquitin-proteasome system to degrade the target protein, such as, but not limited to, ARV-110, ARD-61, and UT-34. In some specific embodiments, the small molecule compound is ARV-110, with a CAS number of 2222112-77-6 and a molecular formula of C 41 H 43 CIF 9 O 6 , molecular weight is 812.29, purity ≥98% LC / MS.
[0062] It should be understood that "androgen receptor inhibitor" also includes androgen receptor protein variants with altered activity or polynucleotides encoding the protein variants, or a combination thereof.
[0063] The "variant" of the androgen receptor protein can be (i) a protein in which one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) are substituted, and such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) a protein with a substitution group in one or more amino acid residues, or (iii) a protein formed by fusion of an additional amino acid sequence to this protein sequence, or (iv) a biologically active fragment of the protein, etc.
[0064] It should be understood that the androgen receptor protein variant or the polynucleotide (gene) encoding the protein variant for targeted inhibition of the expression or activity of the androgen receptor may be a variant with reduced activity or an inactive variant, for example, showing a weak response or no response to androgen. For example, hundreds of androgen receptor protein or gene variants found in androgen insensitivity syndrome (AIS) are included in the scope of the androgen receptor protein or the polynucleotide (gene) encoding the protein described in the present invention.
[0065] It should be understood that although the AR gene or protein of the present invention is preferably obtained from humans or mice, other genes or proteins obtained from other species (e.g., mammalian sources) that are highly homologous to human or mouse AR genes or proteins (e.g., having more than 80%, such as 85%, 90%, 95%, or even 98% sequence identity), or genes with degeneracy with the genes are also within the scope of the present invention. Methods and tools for comparing sequence identity are also well known in the art, such as BLAST.
[0066] Compositions, pharmaceutical compositions and kits
[0067] Herein, the cytokine refers to a cytokine that can be combined with an androgen receptor inhibitor to inhibit androgen receptor. Exemplarily, the cytokine is a combination of IL-15 and IL-7.
[0068] The present invention provides a composition comprising an androgen receptor inhibitor and a cytokine, wherein the cytokine is a combination of IL-15 and IL-7.
[0069] In the composition, the concentration of cytokines IL-15 and IL-7 can be 5-50 ng / mL, respectively, for example 5 ng / mL, 6 ng / mL, 7 ng / mL, 8 ng / mL, 9 ng / mL, 10 ng / mL, 15 ng / mL, 20 ng / mL, 25 ng / mL, 30 ng / mL, 35 ng / mL, 40 ng / mL, 45 ng / mL, 50 ng / mL or a range between any two of the above values.
[0070] In the composition, when the androgen receptor inhibitor is ARV-110, its concentration can be 1-10 nM, such as 1 nM, 2 nM, 3 nM, 4 nM, 5 nM, 6 nM, 7 nM, 8 nM, 9 nM, 10 nM or a range between any two of the above values.
[0071] Herein, the composition may be a pharmaceutical composition. Therefore, the present invention also provides a pharmaceutical composition comprising an androgen receptor inhibitor, a cytokine and a pharmaceutically acceptable excipient, wherein the cytokine is a combination of IL-15 and IL-7.
[0072] Herein, the term "pharmaceutically acceptable excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995). Pharmaceutically acceptable excipients include, but are not limited to, diluents, carriers, solubilizers, emulsifiers, preservatives and / or adjuvants. The excipient is preferably nontoxic to the recipient at the dose and concentration used. Such excipients include, but are not limited to, saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. In certain embodiments, the pharmaceutical composition may contain substances for improving, maintaining or retaining, for example, the pH, permeability, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution or release rate, absorption or penetration of the composition. These substances are known in the prior art. The optimal pharmaceutical composition can be determined based on the expected route of administration, delivery method, and required dosage.
[0073] Pharmaceutical compositions for in vivo administration are usually provided in the form of sterile preparations. Sterilization is achieved by filtering through a sterile filtration membrane. When the composition is freeze-dried, this method can be used for sterilization before or after freeze-drying and rehydration. The pharmaceutical composition of the present invention can be selected for parenteral delivery. Compositions for parenteral administration can be stored in freeze-dried form or in solution. For example, they are prepared by conventional methods with physiological saline or aqueous solutions containing glucose and other adjuvants. Parenteral compositions are usually placed in containers with sterile access holes, such as intravenous solution strips or vials with stoppers that can be pierced by hypodermic injection needles. Alternatively, the composition can be selected for inhalation or delivery through the digestive tract (such as oral). The preparation of the pharmaceutically acceptable composition is within the technology of the art. Other pharmaceutical compositions will be apparent to those skilled in the art. Technologies for preparing a variety of other sustained or controlled delivery methods (such as liposome carriers, bioerodible microparticles or porous beads and depot injections) are also known to those skilled in the art.
[0074] Once the pharmaceutical composition is formulated, it is stored in a sterile vial in the form of a solution, suspension, gel, emulsion, solid, crystal, or in a dehydrated or lyophilized powder. The formulation can be stored in a ready-to-use form or in a form that is rehydrated (e.g., lyophilized) before administration.
[0075] The present invention also provides a kit comprising an androgen receptor inhibitor and a cytokine, wherein the cytokine is a combination of IL-15 and IL-7. The kit may also include a culture medium suitable for culturing T cells, thereby being used to culture and prepare T cells. The culture medium may also include a basal culture medium (e.g., RPMI 1640 complete culture medium), serum, antibiotics, growth factors, and other substances suitable for T cell culture.
[0076] Method for preparing T cells with persistent killing ability and application thereof
[0077] The present invention provides a method for preparing T cells with persistent killing ability, the method comprising: using an androgen receptor inhibitor and a combination of cytokines IL-15 and IL-7, or incubating T cells with the combination, thereby obtaining T cells with persistent killing ability.
[0078] In some specific embodiments, the incubation time can be 24 hours to 20 days, such as 5-10 days. The density of T cells during incubation is not limited, for example, it can be 1×10 6 / mL~2×10 6 / mL. The incubation temperature can be 37 degrees, the carbon dioxide concentration can be 5%, and the humidity is not limited as long as it is suitable for T cell growth.
[0079] Exemplary, during incubation, the concentration of cytokines IL-15 and IL-7 can be 5-50ng / mL, such as 5ng / mL, 6ng / mL, 7ng / mL, 8ng / mL, 9ng / mL, 10ng / mL, 15ng / mL, 20ng / mL, 25ng / mL, 30ng / mL, 35ng / mL, 40ng / mL, 45ng / mL, 50ng / mL or the range between any two of the above values. When the androgen receptor inhibitor is ARV-110, its concentration can be 1-10nM, such as 1nM, 2nM, 3nM, 4nM, 5nM, 6nM, 7nM, 8nM, 9nM, 10nM or the range between any two of the above values.
[0080] The present invention also provides an isolated T cell with persistent killing ability, which is prepared by the preparation method described in any embodiment of the present invention.
[0081] The present invention also provides the use of the composition, or the combination of the androgen receptor inhibitor and the cytokines IL-15 and IL-7 in preparing T cells with persistent killing ability.
[0082] The "T cells with persistent killing ability" described in the present invention can be T cells or T cell lines from animals (especially mammals). In some embodiments, the T cells are cells derived from mammalian peripheral blood, stem cells / progenitor cells, or induced pluripotent stem cells (iPSCs), or can be mature commercial cell line products.
[0083] T cells with persistent killing ability also include T cells that have been genetically engineered to express exogenous proteins, such as TCR-T cells or CAR-T cells. Generally, T cells can be genetically engineered before, during or after the implementation of the culture method of the present invention, so that nucleic acid molecules of interest (e.g., for expressing proteins such as CAR) enter (e.g., by transfection) T cells. Therefore, the T cells can be T cells for immune cell therapy. The T cells can also be used for non-therapeutic purposes, such as research, drug production, quality control and other purposes.
[0084] The T cells in the present invention include but are not limited to CD8 + T cells, CD4 + T cells, CD44 + T cells, CD62L + T cells, TCF1 + T cells, TCF1 + TIM3 - T cells, SLAMF6 + TIM3 - T cells, IFNγ + TNFα + T cells, CD44 + CD62L + T cells, Thy1.1 + T cells, Ki67 + T cells, CD107a + Granzyme B + T cells, TCR-T cells, CAR-T cells. T cells can be collected from peripheral blood, lymph nodes, thymus, bone marrow, tumors, pleural effusion, ascites or umbilical cord blood. For example, T cells can be recovered from peripheral blood by density centrifugation. Peripheral blood can be derived from healthy sources such as the patient himself, blood donors, non-blood donors, etc. In an exemplary embodiment, mouse T cells are cultured from lymph nodes. The T cells can be prepared as an injection for administration, and the injection is for example, but not limited to: intradermal injection, subcutaneous injection, intramuscular injection, intravenous injection.
[0085] It should be understood that since the combination of androgen receptor inhibitor and cytokines IL-15 and IL-7 can be used to prepare T cells with persistent killing ability, the composition or pharmaceutical composition of the present invention can also include the T cells with persistent killing ability.
[0086] Methods and applications for treating tumors
[0087] The androgen receptor inhibitor and cytokine IL-15 and IL-7 combination of the present invention, the composition, pharmaceutical composition and / or T cell can be used to prepare a drug for treating tumors. Therefore, the present invention provides the androgen receptor inhibitor and cytokine IL-15 and IL-7 combination, the use of the composition, pharmaceutical composition and / or T cell in the preparation of a drug for treating tumors. The present invention also provides a method for treating tumors, comprising administering the androgen receptor inhibitor and cytokine IL-15 and IL-7 combination of the present invention, or the composition, pharmaceutical composition and / or T cell of the present invention to a subject in need.
[0088] The terms "patient", "subject", "individual", "object" are used interchangeably herein and include any organism, such as an animal, preferably a mammal (e.g., a human, rat, mouse, dog, cat, rabbit, etc.), more preferably a human. In some preferred embodiments, the subject is male.
[0089] The term "tumor" is a swelling or lesion formed by an abnormal growth of cells (called tumor cells or tumor cells). A "tumor cell" is an abnormal cell that is divided by rapid, uncontrolled cell proliferation and continues to divide after the stimulus that triggers new divisions has ceased. Tumors show a partial or complete lack of structural organization and functional coordination with normal tissues. Typically, they form a distinct mass of tissue, whether benign, pre-malignant or malignant. The tumor of the present invention can be a primary or metastatic tumor. Exemplary, the tumor can be, but is not limited to: colon cancer, liver cancer, small cell lung cancer, non-small cell lung cancer, melanoma, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, gastric cancer, Kaposi's sarcoma, squamous cell carcinoma.
[0090] The term "treatment" refers to the use of any of the embodiments of "treating tumors" described herein to achieve at least one positive therapeutic effect (e.g., a decrease in the number of tumor cells, a decrease in tumor volume, a decrease in the rate of tumor cell infiltration into peripheral organs, a decrease in the number of tumor metastases, a decrease in the rate of tumor metastasis or tumor growth, an increase in life expectancy, or a decrease in various physiological symptoms associated with cancer). The treatment regimen that effectively treats a subject may vary according to a variety of factors (e.g., the patient's disease state, age, weight, and the ability of the therapy to stimulate an anti-cancer response in the subject).
[0091] For administration, the therapeutically effective amount (also referred to as dosage) can be preliminarily estimated based on the results of in vitro assays, animal model studies and / or preclinical studies. Such information can be used to more accurately determine the useful dose of an object of interest. Particularly useful preclinical tests include measurements of cell growth, cell death, cell viability, or measurements of tumor size, volume, etc. in an animal. The actual dose administered to a particular subject can be determined by a physician, veterinarian, or researcher in the context of parameters such as physical, physiological, and psychological factors (including delivered molecules, indications, routes of administration, patient's body weight, patient's body surface or organ size, patient's age and general health, etc.), previously or simultaneously performed therapeutic interventions, subject's idiopathicity, and routes of administration. In certain embodiments, clinicians can titrate dosages and change routes of administration to obtain optimal therapeutic effects. For example, about 10 micrograms / kg body weight-about 50 milligrams / kg body weight per day.
[0092] In a specific embodiment of the present invention, in an animal experiment on mice, a dosage regimen of an androgen receptor inhibitor, a cytokine IL-15 and an IL-7 combination is proposed. It is easy for a person skilled in the art to convert the dosage of mice into a dosage suitable for humans, for example, it can be calculated according to the Meeh-Rubner formula:
[0093] Meeh-Rubner formula: A=k×(W2 / 3) / 10,000.
[0094] Where A is body surface area, calculated in m2; W is body weight, calculated in g; K is a constant, which varies with the species of animal: 9.1 for mice and rats, 9.8 for guinea pigs, 10.1 for rabbits, 9.9 for cats, 11.2 for dogs, 11.8 for monkeys, and 10.6 for humans.
[0095] When necessary, the composition, pharmaceutical composition and / or T cells of the present invention may also be administered in combination with other therapies, active ingredients or drugs. Other therapies include, but are not limited to, chemotherapy, radiotherapy, and immunotherapy. Other active ingredients or drugs include, but are not limited to, immune checkpoint inhibitors.
[0096] The frequency of administration will depend on the pharmacokinetic parameters of the T cells in the formulation used. The clinician typically administers the composition until a dose is achieved to achieve the desired effect. The composition can therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implant device or catheter.
[0097] The route of administration of the pharmaceutical composition is according to known methods, for example, orally, by injection via intravenous, intraperitoneal, intracerebral (intracerebroparenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, portal vein or intralesional routes; by sustained release systems or by implant devices.
[0098] The present invention also provides a drug kit for treating tumors, wherein the drug kit contains an androgen receptor inhibitor, cytokines IL-15 and IL-7. The drug kit may also contain T cells, such as T cells prepared by the method of the present invention.
[0099] The androgen receptor inhibitor, cytokine IL-15, IL-7 and / or T cells can be placed in one container or in different containers.
[0100] The medicine kit may also contain a pharmaceutically acceptable carrier, and / or auxiliary medication materials, such as a syringe for injection, etc.
[0101] In addition, the medicine kit may also contain instructions for use, describing the method for treating tumors.
[0102] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0103] Experimental Materials
[0104] 1. Sequence
[0105] SEQ ID NO: 1: Human AR protein sequence:
[0106] MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGLEGESLGCSGSAAAGSSGTLELPSTLSLYKSGALDEAAAYQSRDYYNFPLALAGPPPPPPPPHPHARIKLENPLDYGSAWAAAAAQCRYGDLASLHGAGAAGPGSGSPSAAASSSWHTLFTAEEGQLYGPCGGGGGGGGGGGGGGGGGGGGGGGEAGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGPWMDSYSGPYGDMRLETARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGEASSTTSPTEETTQKLTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ
[0107] SEQ ID NO:2: Mouse AR protein sequence:
[0108] MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREAIQNPGPRHPEAANIAPPGACLQQRQETSPRRRRRQQHTEDGSPQAHIRGPTGYLALEEEQQPSQQQAASEGHPESSCLPEPGAATAPGKGLPQQPPAPPDQDDSAAPSTLSLLGPTFPGLSSCSADIKDILNEAGTMQLLQQQQQQQQHQQQHQQHQQQQEVISEGSSARAREATGAPSSSKDSYLGGNSTISDSAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYASLLGGPPAVRPTPCAPLPECKGLPLDEGPGKSTEETAEYSSFKGGYAKGLEGESLGCSGSSEAGSSGTLEIPSSLSLYKSGALDEAAAYQNRDYYNFPLALSGPPHPPPPTHPHARIKLENPLDYGSAWAAAAAQCRYGDLGSLHGGSVAGPSTGSPPATTSSSWHTLFTAEEGQLYGPGGGGGSSSPSDAGPVAPYGYTRPPQGLTSQESDYSASEVWYPGGVVNRVPYPSPNCVKSEMGPWMENYSGPYGDMRLDSTRDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGENSNAGSPTEDPSQKMTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ
[0109] Table 1 Nucleotide sequences used in the present invention
[0110] shRNA sequence (to construct gene knockdown cells): SEQ ID NO:3:Murine Ar F:GACGATTGTACCATTGATAAA SEQ ID NO:4:Murine Ar R:TTTATCAATGGTACAATCGTC SEQ ID NO:5:Scramble F:GTCACGATAAGACAATGA SEQ ID NO:6:Scramble R:TCATTGCTTATCGTGAC qPCR primer sequences: SEQ ID NO:7:Ar F:TGCCCGAATGCAAAGGTCTT SEQ ID NO:8:Ar R:TTGGCGTAACCTCCCTTGAAA SEQ ID NO:9:Tcf7 F:AGCTTTCTCCACTCTACGAACA SEQ ID NO:10:Tcf7 R:AATCCAGAGAGATCGGGGGTC SEQ ID NO:11:Klf2 F:GCGTACACACACAGGTGAGA SEQ ID NO:12:Klf2 R:GCACAAGTGGCACTGAAAGG SEQ ID NO:13:Actb F:GGCTGTATTCCCCTCCATCG SEQ ID NO:14:Actb R:CCAGTTGGTAACAATGCCATGT
[0111] 2. Experimental reagents
[0112] The reagents used in the present invention are shown in Table 2-7 below:
[0113] Table 2
[0114]
[0115]
[0116] Table 3
[0117]
[0118] Table 4
[0119]
[0120] Table 5
[0121]
[0122] Table 6
[0123]
[0124]
[0125] Table 7
[0126]
[0127] Example
[0128] Example 1: Using RNAi viral vectors to deliver shRNA to knock down AR expression in T cells
[0129] Experimental methods:
[0130] 1. Preparation of RNAi virus particles: The highly active shRNA targeting the mouse androgen receptor gene (Ar shRNA: GACGATTGTACCATTGATAAA, SEQ ID NO: 3) and the control shRNA without specific targeting of any gene function (Scramble shRNA: GTCACGATAAGACAATGA, SEQ ID NO: 5) were cloned into the retroviral vector RNAi-Ready pSIREN-RetroQ-mcherry (the vector was transformed from the pSIREN-RetroQ plasmid, and the original puromycin resistance gene was replaced by the mcherry expression gene), and packaged into pSIREN-RetroQ-Ar-shRNA virus and pSIREN-RetroQ-Scramble-shRNA control virus using Pheonix 293T cells.
[0131] 2. T cell virus infection: Two male 2C-TCR transgenic mice were euthanized by cervical dislocation, and lymph nodes were removed and ground through a 70 μm filter to prepare a single cell suspension. The cells were resuspended in RPMI 1640 complete medium containing 1 μmol / L SIY antigen peptide and incubated at 37°C with 5% CO. 2 After 24 h of activation, activated 2C-TCR CD8 + T cells, the cell pellet was centrifuged and resuspended in complete medium containing 10 ng / ml of IL-7 and IL-15 to a density of 1.5 × 10 6 / mL, transferred to a 24-well culture plate, 1ml of cell suspension per well, 1ml of retroviral supernatant was added, and to improve the efficiency of virus infection, 6ng / ml GMPO Polybrene was used, and the infection was carried out by centrifugation at 30℃ and 2000rpm for 90min (the speed increase was 1 and the speed decrease was 0); after the centrifugation, the cells were cultured in the incubator for 4h and half of the medium was replaced; the next day, the cells were evenly divided into two wells and the virus was infected again.
[0132] 3. Androgen receptor knockdown efficiency detection: CD8 after infection + T cells were continuously expanded for 3-5 days using RPMI 1640 full culture medium containing 10 ng / ml of IL-7 and IL-15, and AR knockdown T cells (Ar shRNA) and control group T cells (Scramble shRNA) were obtained. Flow cytometry was used to detect the efficiency of viral infection, and real-time fluorescence quantitative PCR and Western Blotting were used to detect AR gene transcription and protein expression in T cells to clarify the AR knockdown efficiency in T cells using the shRNA method.
[0133] 4. Statistical analysis: The experimental results were statistically analyzed using Prism software (GraphPad Prism 8.0 software). Data were expressed as mean ± SEM, and the data were in accordance with normal distribution. Parameter tests were used, and the differences between the two groups were statistically analyzed using Student's t tests (unpaired, two-tailed). **P < 0.01.
[0134] The results are as follows Figure 1 As shown. Real-time fluorescence quantitative PCR results show that shRNA targeting the mouse AR gene can achieve a knockdown efficiency of 70% ( Figure 1 Left). Western Blotting results show that AR protein can be efficiently knocked out in mouse T cells ( Figure 1 right).
[0135] Example 2: Knockdown of AR expression in T cells can enhance the anti-tumor properties of T cells
[0136] Experimental methods:
[0137] 1. T cell function index detection: AR knockdown T cells obtained in Example 1 were cultured at a density of 1.5×10 6 / mL was inoculated into 96-well round-bottom plates, 200μL of cell suspension was added to each well, and the cells were incubated in a cell culture incubator for 5h using PMA / Ionomycine Cell Stimulation Cocktail (plus protein transport inhibitors) to stimulate cytokine release and block its transport in the Golgi apparatus. Subsequent cell flow cytometry staining was used to detect the secretion levels of intracellular effector cytokines such as IFN-γ and TNF-α, and to analyze the double-positive multifunctional CD8 + T cell subset ratio.
[0138] 2. T cell stemness index detection: AR knockdown T cells obtained in Example 1 were cultured at a density of 1.5×10 6 / mL was inoculated into a 96-well round-bottom plate, with 200 μL of cell suspension per well, and CD8 was stimulated again using antibodies against CD3 (1 μg / mL) and CD28 (1 μg / mL). + T cells were incubated in a cell culture incubator for 24 h and were characterized by double positivity for CD44 and CD62L. + T cell subsets were identified and their proportions were analyzed; at the same time, molecular markers related to T cell stemness were further detected in the activated T cell subsets that were double positive for PD-1 and CD44, including the surface molecule SLAMF6 and the transcription factor TCF1.
[0139] 3. Evaluation of T cell therapy effect: First, subcutaneous tumors were established in mice using B16F1-EGFR-SIY mouse melanoma cells. This cell line can be activated by 2C-TCR CD8 + T cells specifically recognize and kill. After that, about 8-10 days after tumor inoculation, the tumor volume can reach 100mm 3 , were randomly divided into three groups: two groups were T cell treatment groups, and AR knockdown 2C-TCR CD8 + T cells (Ar shRNA group) and control 2C-TCR CD8 + T cells (Scramble shRNA group), 2×10 6 The other group was injected intravenously with an equal volume of PBS as the untreated group. Finally, a vernier caliper was used to track and record the tumor growth.
[0140] 4. Statistical analysis: The experimental results were statistically analyzed using Prism software (GraphPad Prism 8.0 software). Data were expressed as mean ± SEM, and the data were in accordance with normal distribution. Parametric tests were used. The differences between the two groups were statistically analyzed using Student's t tests (unpaired, two-tailed), and the differences between multiple groups were analyzed using two-way ANOVA. The parametric post-test was Turkey test. The significant differences correspond to the following: * is P < 0.05; ** is P < 0.01; *** is P < 0.001; ns means no statistical difference.
[0141] The results are as follows Figure 2 As shown. The results of flow cytometry detection of intracellular cytokines IFN-γ and TNF-α showed that AR knockdown T cells had stronger ability to secrete effector cytokines ( Figure 2 A) In addition, after AR knockdown, CD44 and CD62L double-positive memory-like CD8 + T cell subsets induced upregulation ( Figure 2 B). Further analysis of the expression levels of stemness-related molecular markers (SLAMF6) and transcription factors (TCF1) showed that stem cell-like CD8 + T cell subset ratio (SLAMF6 + TIM3 - or TCF1 + TIM3-) was significantly increased in AR knockdown T cells ( Figure 2 C). At the same time, the results of the T cell therapeutic reinfusion experiment in tumor-bearing mice showed that AR knockdown T cells performed better in inhibiting tumor progression ( Figure 2 D).
[0142] Example 3: Reprogramming T cell anti-tumor functional properties using androgen receptor degraders
[0143] Experimental methods:
[0144] 1. In vitro T cell stemness potential analysis: First, through cell-level screening, the appropriate concentration of ARV-110 for targeted degradation of androgen receptor protein in T cells was 1nM-10nM. Then, 2C-TCR transgenic mice were used to obtain lymph node single cell suspension, and 2C-TCR CD8 + Next, 2C-TCRCD8 cells were centrifuged + T cells were collected at a density of 1.5 × 10 6 / mL was inoculated into 24-well culture plates, 1 ml of cell suspension was added to each well, 1 nM ARV-110 was added to RPMI 1640 complete medium, and a combination of cytokines of IL-7 and IL-15 (10 ng / ml each) was used for treatment. Finally, 2C-TCR CD8 + The T cell density was 1.5×10 6 / mL, and the combination of ARV-110 (1nM), IL-7 (10ng / ml) and IL-15 (10ng / ml) was used to maintain the culture for 3-5 days before detection and analysis. Western Blotting to detect CD8 + AR protein degradation efficiency in T cells; flow cytometry detection of CD44 and CD62L memory-like CD8 + T cell formation ratio; in addition, the real-time fluorescence quantitative PCR method was used to analyze the gene transcription levels of TCF1 and KLF2, the key transcription factors for maintaining T cell stemness.
[0145] 2. Evaluation of in vivo T cell therapy: First, subcutaneous tumors were established in mice using B16F1-EGFR-SIY mouse melanoma cells. This cell line can be activated by 2C-TCR CD8 + T cells specifically recognize and kill. After that, about 8-10 days after tumor inoculation, the tumor volume can reach 100mm 3 The patients were randomly divided into three groups: two of them were T cell treatment groups, and the 2C-TCR CD8+ T cells prepared by ARV-110 treatment (ARV-110 2C-TCR group) and the control 2C-TCR CD8+ T cells treated with DMSO were infused through the orbital vein. + T cells (DMSO 2C-TCR group), 2×10 6 The other group was injected with an equal volume of PBS as the untreated group. Finally, the tumor volume was measured using a vernier caliper and the tumor growth curve was drawn.
[0146] 3. Characterization of therapeutic T cells in vivo: Using the 2C-TCR CD8 +In the T cell therapeutic reinfusion model, the tumor tissue was removed 10 days after adoptive reinfusion and digested with DNase I and collagenase I to prepare a single cell suspension of tumor tissue. Because therapeutic T cells carry the Thy1.1 label and can be distinguished from endogenous T cells, flow cytometry was used to detect the proportion of therapeutic T cell infiltration in the tumor, and the proliferation marker Ki67 was used to characterize the proliferation potential of T cells; in addition, the effector cytokine secretion ability of therapeutic T cells in the tumor and lymph nodes was analyzed by detecting TNF-α and IFN-γ levels, and the degranulation ability of therapeutic T cells was analyzed by CD107a and granzyme B levels.
[0147] 4. Statistical analysis: The experimental results were statistically analyzed using Prism software (GraphPad Prism 8.0 software). Data were expressed as mean ± SEM, and the data were in accordance with normal distribution. Parametric tests were used. The differences between the two groups were statistically analyzed using Student's t tests (unpaired, two-tailed), and the differences between multiple groups were analyzed using two-way ANOVA. The parametric post-test was Turkey test. The significant differences correspond to the following: * is P < 0.05; ** is P < 0.01; *** is P < 0.001; ns means no statistical difference.
[0148] The results are as follows Figure 3-5 Western Blotting results showed that the androgen receptor degrader ARV-110 can effectively degrade AR expression in T cells ( Figure 3 A). Further flow cytometry and real-time fluorescence quantitative PCR results showed that AR molecule degradation can promote memory-like CD8 + Formation and maintenance of T cell subsets Figure 3 B), while the transcriptional expression levels of stemness transcription factors TCF1 (encoded by Tcf7 gene) and KLF2 gene increased ( Figure 3 C), indicating that AR degradation can achieve T cell stemness reprogramming. The therapeutic T cell transfusion experiment in tumor-bearing mice showed that T cells after AR degradation have stronger tumor suppression ability ( Figure 4 ). Further testing of the function and characterization of intratumoral T cells showed that the T cells with AR degradation had a higher tumor infiltration rate, stronger proliferation ability, effector cytokine and degranulation ability ( Figure 5 AD).
[0149] Example 4: IL-7 and IL-15 cytokine combination can enhance the potential of androgen receptor inhibition to induce memory-like T cells
[0150] Experimental methods:
[0151] 1. T cell treatment: According to the experimental method in Example 1, obtain AR knockdown 2C-TCR CD8 + T cells were collected at a density of 1.5 × 10 6 / mL was inoculated into a 24-well flat-bottom plate (1mL cell suspension per well). At the same time, the experimental group cell culture medium was added with IL-7 (10ng / mL) and IL-15 (10ng / mL) cytokine combination for incubation; while the control group did not add any cytokines. After the cells were maintained in the cell culture incubator for 3-5 days, subsequent flow cytometry analysis was performed.
[0152] 2. T cell phenotype detection: 2C-TCR CD8 cultured with IL-7 and IL-15 cytokines + Flow cytometry analysis of T cells: characterization of memory-like CD8 using double positivity for CD44 and CD62L + T cell subsets were identified and their proportions were analyzed; in addition, intracellular staining was used to evaluate the effects of cytokine combination treatment combined with AR gene knockdown on T cell stemness and proliferation using the stemness transcription factor TCF1 and the cell proliferation marker Ki67.
[0153] 3. Statistical analysis: The experimental results were statistically analyzed using Prism software (GraphPad Prism 8.0 software). Data were expressed as mean ± SEM, and the data were in accordance with normal distribution. Differences among multiple groups were analyzed using two-way ANOVA. Significant differences correspond to the following: ** means P < 0.01; *** means P < 0.001; ns means no statistical difference.
[0154] The results are as follows Figure 6 The results of flow cytometry analysis showed that the combined treatment of IL-7 and IL-15 cytokines significantly increased the expression of CD44 and CD62L double-positive memory-like CD8 + The proportion of T cell subsets; at the same time, combined with AR gene knockdown, it is more conducive to the formation of memory-like T cell subsets ( Figure 6 A). Further analysis of the expression levels of stemness-related transcription factor TCF1 and proliferation marker Ki67 showed that combined treatment with IL-7 and IL-15 cytokines combined with AR gene knockdown significantly improved T cell proliferation potential and stemness maintenance ability ( Figure 6 B).
[0155] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.
Claims
1. Use of androgen receptor inhibitors and cytokines in the preparation of T cells with persistent killing ability, wherein the cytokines are IL-15 and IL-7; the androgen receptor inhibitor is a small molecule compound, an inhibitory polynucleotide, or a combination thereof.
2. The use according to claim 1, characterized in that The androgen receptor inhibitor is a shRNA or siRNA targeting an androgen receptor coding sequence; preferably, the shRNA has a sequence as shown in SEQ ID NO: 3 or SEQ ID NO: 4, or a sequence having at least 90% sequence identity with the sequence as shown in SEQ ID NO: 3 or SEQ ID NO: 4; or, The androgen receptor inhibitor is a small molecule compound that has the function of degrading androgen receptor protein; preferably ARV-110, ARD-61 or UT-34.
3. The use according to claim 1, characterized in that The concentrations of IL-15 and IL-7 are 1 to 50 ng / mL, preferably 10 to 20 ng / mL, and / or The concentration of the androgen receptor inhibitor is 0.1 to 10 nM, preferably 1 to 5 nM.
4. The use according to claim 1, characterized in that The T cells include: CD8 + T cells, CD4 + T cells, CD44 + T cells, CD62L + T cells, TCF1 + T cells, TCF1 + TIM3 - T cells, SLAMF6 + TIM3-T cells, CD44 + CD62L + T cells, IFNγ + TNFα + T cells, Thy1.1 + T cells, Ki67 + T cells, CD107a + Granzyme B + T cells, TCR-T cells and CAR-T cells.
5. A method for preparing T cells with persistent killing ability, the method comprising: Incubating T cells with androgen receptor inhibitors, cytokines IL-15 and IL-7 to obtain T cells with persistent killing ability; wherein the androgen receptor inhibitor is a small molecule compound, an inhibitory polynucleotide, or a combination thereof; Preferably, the androgen receptor inhibitor is as defined in claim 2; Preferably, the concentrations of the androgen receptor inhibitor, cytokines IL-15 and IL-7 are as defined in claim 3; Preferably, the T cell is as defined in claim 4; Preferably, the incubation time is 24 hours to 20 days, more preferably 5-10 days; and / or, preferably, the density of T cells during incubation is 1×10 6 / mL~2×10 6 / mL.
6. A T cell with persistent killing ability, characterized in that: The T cells are prepared by the method according to claim 5.
7. A composition comprising an androgen receptor inhibitor, cytokines IL-15 and IL-7, wherein: The androgen receptor inhibitor is a small molecule compound, an inhibitory polynucleotide, or a combination thereof; Preferably, the androgen receptor inhibitor is as defined in claim 2; Preferably, the concentrations of the androgen receptor inhibitor, cytokines IL-15 and IL-7 are as defined in claim 3; Preferably, the composition further comprises T cells with persistent killing ability as described in claim 6; more preferably, the T cells are as defined in claim 4.
8. A pharmaceutical composition comprising an androgen receptor inhibitor, cytokines IL-15, IL-7, and a pharmaceutically acceptable carrier; wherein: The androgen receptor inhibitor is a small molecule compound, an inhibitory polynucleotide, or a combination thereof; Preferably, the androgen receptor inhibitor is as defined in claim 2; Preferably, the concentrations of the androgen receptor inhibitor, cytokines IL-15 and IL-7 are as defined in claim 3; Preferably, the pharmaceutical composition further comprises the T cells with persistent killing ability as claimed in claim 6; more preferably, the T cells are as defined in claim 4.
9. A kit or a drug kit comprising an androgen receptor inhibitor, cytokines IL-15 and IL-7, wherein: The androgen receptor inhibitor is a small molecule compound, an inhibitory polynucleotide, or a combination thereof; Preferably, the kit or drug box further contains the T cells with persistent killing ability as claimed in claim 6, or the composition as claimed in claim 7, or the pharmaceutical composition as claimed in claim 8; more preferably, the T cells are as defined in claim 4; Preferably, the androgen receptor inhibitor is as defined in claim 2; Preferably, the concentrations of the androgen receptor inhibitor, cytokines IL-15 and IL-7 are as defined in claim 3.
10. Use of the T cell with persistent killing ability as claimed in claim 6, or the composition as claimed in claim 7, or the pharmaceutical composition as claimed in claim 8 in the preparation of a drug for treating tumors; Preferably, the tumor is a primary or metastatic tumor; more preferably, the tumor is selected from one or more of the following: colon cancer, liver cancer, small cell lung cancer, non-small cell lung cancer, melanoma, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, gastric cancer, Kaposi's sarcoma and squamous cell carcinoma.
Citation Information
Cited By
Novel targeted degradation platform and application thereof in tumor immunotherapy
CN122381205A
